ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ABVX vs IONS // EV/EBITDA & P/E VALUATION

Abivax SA (NASDAQ) VS. Ionis Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: ABVX 8 — IONS 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ABVX VS. IONS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ABVX IONS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 96.00% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 9.90% -20.90% +30.80 ABVX /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 21.0x — — TIE /valuation <GO>
Free Cash Flow Yield 2.21% -4.34% +6.55 ABVX /fcf-yield <GO>
Operating Margin 13.90% -40.40% +54.30 ABVX /operating-margins <GO>
Net Profit Margin 10.90% -40.40% +51.30 ABVX /net-margins <GO>
Revenue Growth (YoY) 8.80% 33.80% -25.00 IONS /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 3.74 1.08 +2.66 ABVX /balance-sheet <GO>
Piotroski F-Score Quality 8/9 5/9 +3.00 ABVX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 38.7 36.2 +2.50 ABVX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 1.05 1.09 -0.04 IONS /macro-sensitivity <GO>
Forward P/E Multiple 30.5x 22.0x +8.50 IONS /forward-pe <GO>
Enterprise Scale & Market Cap $7.41B $6.85B $555.3M ABVX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ABVX REV IONS REV ABVX GROSS % IONS GROSS % ABVX FCF IONS FCF
FY 2025 — $943.7M — 98.3% — -$320.0M
FY 2024 — $705.1M — 98.4% — -$546.2M
FY 2023 — $787.6M — — — -$343.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ABVX // BETA 1.05
IONS // BETA 1.09